The Heat Death Line: Proposed Heat Index Alert Threshold for Preventing Heat-Related Fatalities in the Civilian Workforce

Author(s):  
Zaw Maung ◽  
Aaron W. Tustin

A threshold Heat Index (HI) can serve as the basis for advising the civilian workforce about the risk of heat-related illnesses. We conducted a systematic review and compiled reports of work-related fatalities from heat-related illnesses. We calculated the HI for each fatality. Our objective was to expand upon the military’s concept of a “heat death line” and identify an HI alert threshold for the civilian workforce. We identified 14 publications totaling 570 heat-related deaths. In the meta-analysis, the median HI was 101 with a range of 62 to 137. Almost all deaths (96 percent and 99 percent of civilian and military fatalities, respectively) occurred when HI ≥80, which is our proposed heat death line. Some existing HI-based heat advisories are set at a higher temperature value. However, many occupational heat-related illnesses occur below these thresholds, resulting in low sensitivity and a false sense of security. In at-risk outdoor industries, HI ≥80 should trigger hazard awareness and protective actions.

2004 ◽  
Author(s):  
Thomas Ng ◽  
Jill A. Brown ◽  
Robert J. Vandenberg
Keyword(s):  

Author(s):  
Laurie Essig

In Love, Inc., Laurie Essig argues that love is not all we need. As the future became less secure—with global climate change and the transfer of wealth to the few—Americans became more romantic. Romance is not just what lovers do but also what lovers learn through ideology. As an ideology, romance allowed us to privatize our futures, to imagine ourselves as safe and secure tomorrow if only we could find our "one true love" today. But the fairy dust of romance blinded us to what we really need: global movements and structural changes. By traveling through dating apps and spectacular engagements, white weddings and Disney honeymoons, Essig shows us how romance was sold to us and why we bought it. Love, Inc. seduced so many of us into a false sense of security, but it also, paradoxically, gives us hope in hopeless times. This book explores the struggle between our inner cynics and our inner romantic.


Author(s):  
Katarzyna Ledwoch ◽  
Maddalena Magoga ◽  
Dulcie Williams ◽  
Stefania Fabbri ◽  
James Walsh ◽  
...  

Abstract Objective: The abundance and prevalence of dry-surface biofilms (DSBs) in hospitals constitute an emerging problem, yet studies rarely report the cleaning and disinfection efficacy against DSBs. Here, the combined impact of treatments on viability, transferability, and recovery of bacteria from DSBs has been investigated for the first time. Methods: Staphylococcus aureus DSBs were produced in alternating 48-hour wet–dry cycles for 12 days on AISI 430 stainless steel discs. The efficacy of 11 commercially available disinfectants, 4 detergents, and 2 contactless interventions were tested using a modified standardized product test. Reduction in viability, direct transferability, cross transmission (via glove intermediate), and DSB recovery after treatment were measured. Results: Of 11 disinfectants, 9 were effective in killing and removing bacteria from S. aureus DSBs with >4 log10 reduction. Only 2 disinfectants, sodium dichloroisocyanurate 1,000 ppm and peracetic acid 3,500 ppm, were able to lower both direct and cross transmission of bacteria (<2 compression contacts positive for bacterial growth). Of 11 disinfectants, 8 could not prevent DSB recovery for >2 days. Treatments not involving mechanical action (vaporized hydrogen peroxide and cold atmospheric plasma) were ineffective, producing <1 log10 reduction in viability, DSB regrowth within 1 day, and 100% transferability of DSB after treatment. Conclusions: Reduction in bacterial viability alone does not determine product performance against biofilm and might give a false sense of security to consumers, manufacturers and regulators. The ability to prevent bacterial transfer and biofilm recovery after treatment requires a better understanding of the effectiveness of biocidal products.


Author(s):  
Joseph Pryce ◽  
Lisa J Reimer

Abstract Background Molecular xenomonitoring (MX), the detection of pathogen DNA in mosquitoes, is a recommended approach to support lymphatic filariasis (LF) elimination efforts. Potential roles of MX include detecting presence of LF in communities and quantifying progress towards elimination of the disease. However, the relationship between MX results and human prevalence is poorly understood. Methods :We conducted a systematic review and meta-analysis from all previously conducted studies that reported the prevalence of filarial DNA in wild-caught mosquitoes (MX rate) and the corresponding prevalence of microfilaria (mf) in humans. We calculated a pooled estimate of MX sensitivity for detecting positive communities at a range of mf prevalence values and mosquito sample sizes. We conducted a linear regression to evaluate the relationship between mf prevalence and MX rate. Results We identified 24 studies comprising 144 study communities. MX had an overall sensitivity of 98.3% (95% CI 41.5, 99.9%) and identified 28 positive communities that were negative in the mf survey. Low sensitivity in some studies was attributed to small mosquito sample sizes (&lt;1,000) and very low mf prevalence (&lt;0.25%). Human mf prevalence and mass drug administration status accounted for approximately half of the variation in MX rate (R 2 = 0.49, p&lt;0.001). Data from longitudinal studies showed that, within a given study area, there is a strong linear relationship between MX rate and mf prevalence (R 2 = 0.78, p &lt; 0.001). Conclusion MX shows clear potential as tool for detecting communities where LF is present and as a predictor of human mf prevalence.


BMJ ◽  
2021 ◽  
pp. n526
Author(s):  
François Lamontagne ◽  
Thomas Agoritsas ◽  
Reed Siemieniuk ◽  
Bram Rochwerg ◽  
Jessica Bartoszko ◽  
...  

Abstract Clinical question What is the role of drugs in preventing covid-19? Why does this matter? There is widespread interest in whether drug interventions can be used for the prevention of covid-19, but there is uncertainty about which drugs, if any, are effective. The first version of this living guideline focuses on the evidence for hydroxychloroquine. Subsequent updates will cover other drugs being investigated for their role in the prevention of covid-19. Recommendation The guideline development panel made a strong recommendation against the use of hydroxychloroquine for individuals who do not have covid-19 (high certainty). How this guideline was created This living guideline is from the World Health Organization (WHO) and provides up to date covid-19 guidance to inform policy and practice worldwide. Magic Evidence Ecosystem Foundation (MAGIC) provided methodological support. A living systematic review with network analysis informed the recommendations. An international guideline development panel of content experts, clinicians, patients, an ethicist and methodologists produced recommendations following standards for trustworthy guideline development using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Understanding the new recommendation The linked systematic review and network meta-analysis (6 trials and 6059 participants) found that hydroxychloroquine had a small or no effect on mortality and admission to hospital (high certainty evidence). There was a small or no effect on laboratory confirmed SARS-CoV-2 infection (moderate certainty evidence) but probably increased adverse events leading to discontinuation (moderate certainty evidence). The panel judged that almost all people would not consider this drug worthwhile. In addition, the panel decided that contextual factors such as resources, feasibility, acceptability, and equity for countries and healthcare systems were unlikely to alter the recommendation. The panel considers that this drug is no longer a research priority and that resources should rather be oriented to evaluate other more promising drugs to prevent covid-19. Updates This is a living guideline. New recommendations will be published in this article and signposted by update notices to this guideline. Readers note This is the first version of the living guideline for drugs to prevent covid-19. It complements the WHO living guideline on drugs to treat covid-19. When citing this article, please consider adding the update number and date of access for clarity.


Author(s):  
Melanie Schubert ◽  
Julia Ludwig ◽  
Alice Freiberg ◽  
Taurai Monalisa Hahne ◽  
Karla Romero Starke ◽  
...  

Stigmatization from work-related COVID-19 exposure has not been investigated in detail yet. Therefore, we systematically searched three databases: Medline, Embase, and PsychInfo (until October 2020), and performed a grey literature search (until February 2021). We identified 46 suitable articles from 24 quantitative and 11 qualitative studies, 6 systematic reviews, 3 study protocols and 1 intervention. The assessment of stigmatization varied widely, ranging from a single-item question to a 22-item questionnaire. Studies mostly considered perceived self-stigma (27 of 35 original studies) in healthcare workers (HCWs) or hospital-related jobs (29 of 35). All articles reported on stigmatization as a result of work-related COVID-19 exposure. However, most quantitative studies were characterized by convenience sampling (17 of 24), and all studies—also those with an adequate sampling design—were considered of low methodological quality. Therefore, it is not possible to determine prevalence of stigmatization in defined occupational groups. Nevertheless, the work-related stigmatization of occupational groups with or without suspected contact to COVID-19 is a relevant problem and increases the risk for depression (odds ratio (OR) = 1.74; 95% confidence interval CI 1.29–2.36) and anxiety (OR = 1.64; 95% CI 1.18–2.28). For promoting workers’ health, anti-stigma strategies and support should be implemented in the workplace.


2008 ◽  
Vol 61 (10) ◽  
pp. 1371-1398 ◽  
Author(s):  
Arie Shirom ◽  
Simona Shechter Gilboa ◽  
Yitzhak Fried ◽  
Cary L. Cooper

2008 ◽  
Vol 183 (7) ◽  
pp. 1317-1317
Author(s):  
Mike Rossner

Sign in / Sign up

Export Citation Format

Share Document